Neutron remains the make-or-break catalyst as RKLB trades near yearly lows despite record backlog

What happened

Rocket Lab’s backlog has reached a record $2.356 billion and first-half 2026 revenue surged 63% year over year, yet the stock sits near yearly lows because investors are fixated on one unflown rocket: Neutron. The medium-lift vehicle has suffered two schedule resets in 2026—first after a January tank rupture and again in October when first launch was pushed into 2027—eroding management’s credibility on delivery timing. While the core Electron and Space Systems businesses are performing well, with 45% of backlog expected to convert within 12 months, the market is unwilling to reward execution without visible Neutron qualification milestones. A successful Neutron debut could revalue the company overnight by unlocking larger launch and constellation opportunities, but the repeated delays have turned that upside into a binary, high-risk event. Until management provides a dated 2027 launch window backed by concrete test evidence, the stock is likely to remain range-bound and vulnerable to further disappointment.

Implication

Near-term entry is unattractive because the stock still prices in medium-lift success despite two Neutron delays and ongoing negative free cash flow. The record backlog and revenue growth offer downside support but do not offset the risk of another schedule slip or qualification failure. A disciplined approach would wait for two catalysts: Q3 2026 results landing within guidance and a filing-backed Neutron milestone that restores credibility. Current holders may maintain positions but should size them knowing that CEO insider sales and heavy ATM dilution already signal insiders are reducing exposure. Aggressive buyers should require a lower entry near $42 or concrete proof that Iridium integration and Neutron de-risking are on track.

Thesis delta

The new article adds no fundamental data but reinforces that Neutron is the sole swing factor for revaluation. My thesis remains unchanged: WAIT until Neutron schedule credibility is restored or the stock falls to a more attractive entry. The article’s emphasis on near-yearly lows is consistent with my bear scenario probability of 25%, but it does not alter the base case that RKLB offers mediocre risk-reward at current prices.